Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Neoadjuvant chemotherapy modulates T cell responses in high-grade serous ovarian cancer metastases

PROVIDER: PRJNA290924 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR2126790_1.fastq.gz	Fastqsanger.gz
	SRR2126790_2.fastq.gz	Fastqsanger.gz
	SRR2126800_1.fastq.gz	Fastqsanger.gz
	SRR2126800_2.fastq.gz	Fastqsanger.gz
	SRR2126791_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 70

Similar Datasets

Neoadjuvant chemotherapy modulates T cell responses in high-grade serous ovarian cancer metastases

2016-07-27 | GSE71340 | GEO

Neoadjuvant chemotherapy modulates T cell responses in high-grade serous ovarian cancer metastases

Project description:Our data suggest that neoadjuvant chemotherapy enhances anti-cancer responses of T cells in peritoneal metastases of patients with high-grade serous ovarian cancer but does not decrease levels of immune checkpoint molecules, providing a rationale for sequential chemo-immunotherapy. tRNA was isolated from 35 omental tissue samples of HGSOC metastases either pre or post NACT treatment. RNASeq was performed on poly-A selected mRNA fragments, 100 b.p paired end, and strand specific, on average 40 million reads per sample.

2016-07-27 | E-GEOD-71340 | biostudies-arrayexpress

Transcriptomes of tumour-associated macrophages from high grade serous ovarian cancer pre- and post-platinum-based neoadjuvant chemotherapy.

Project description:The impact of platinum and taxol based neoadjuvant chemotherapy on tumour-associated macrophages (TAMs) was examined by analysis of TAMs extracted from high grade serous ovarian cancer (HGSOC) samples pre and post chemotherapy.

2021-04-20 | GSE158739 | GEO

Immunologic adapatations of high grade serous ovarian cancer patients to neoadjuvant carboplatin and paclitaxel therapy

Project description:770 genes as well as pathways and deconvoluted immune cell types were determined pre- and post-neoadjuvant chemotherapy in a cohort of 31 stage III-IV high grade serous ovarian cancer (HGSOC) patients, and associations were made with the duration of their platinum-free interval n/a

2022-09-28 | GSE201600 | GEO

Single cell resolution of an open chromatin signature in persister tumor cells

Project description:To characterize transcriptional and chromatin accessibility changes that promote survival of residual cancer following chemotherapy, we performed single-cell multiomic profiling (snRNA+snATAC) on a cohort of non-malignant fallopian tube, treatment-naive, and neoadjuvant chemotherapy (NACT)-treated high-grade serous ovarian cancer (HGSOC) samples. From this analysis, we identified an epigenetic signature that precedes expression and defines the drug-tolerant persister state.

2025-11-13 | GSE293459 | GEO

Longitudinal single-cell RNA-seq data of metastatic ovarian cancer

Project description:We characterized transcriptional patterns of chemotherapy resistance in high-grade serous ovarian cancer (HGSOC) using patient-derived prospective tissue sample pairs before and after treatment at single-cell resolution. Our cohort consists of scRNA-seq data from treatment-naïve and post-neoadjuvant chemotherapy (post-NACT) pairs from 11 homogeneously treated HGSOC patients. After quality control, we obtained 51,786 cells, including 8,806 malignant epithelial (tumor), 8,045 stromal and 34,935 immune cells. Our unbiased analysis reveals how chemotherapy modulates cancer cell states by both subclonal selection and microenvironment boosted transcriptional induction across the homogeneously treated sample cohort. Our results define a cell state that allows biomarker-based prediction and targeting of chemoresistance.

2021-12-24 | GSE165897 | GEO

The impact of neoadjuvant chemotherapy on tumor microenvironment in advanced high-grade serous carcinoma

Project description:High-grade serous ovarian, fallopian tube or peritoneal carcinoma is an aggressive subtype that frequently develops resistance to chemotherapy. It remains controversial whether the resistance is caused by the acquisition of new molecular aberrations or alternatively through the selection of rare preexisting tumor clones. To address this question, we applied single cell RNA sequencing to depict the tumor landscape of a single case of advanced high-grade serous fallopian tube carcinoma during neoadjuvant chemotherapy (NACT).

2022-08-16 | GSE191301 | GEO

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma

Project description:Bulk and single-cell RNA sequencing do not provide full characterization of tissue spatial diversity in cancer samples, and currently available in situ techniques (multiplex immunohistochemistry, imaging mass cytometry) allow for only limited analysis of a small number of targets. The current study represents the first comprehensive approach to spatial transcriptomics of high-grade serous ovarian carcinoma using intact tumor tissue. We selected a small cohort of patients with highly annotated high-grade serous ovarian carcinoma, categorized them by response to neoadjuvant chemotherapy (poor or excellent), and analyzed pre-treatment tumor tissue specimens. Our study uncovered extensive differences in tumor composition between the poor responders and excellent responders to chemotherapy, related to cell cluster organization and localization. This in-depth characterization of high-grade serous ovarian carcinoma tumor tissue from poor and excellent responders showed that spatial interactions between cell clusters may influence chemo-responsiveness more than cluster composition alone.

2021-12-02 | GSE189843 | GEO

Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer

Project description:To characterize the spatial tumor microenvironment (TME) of high-grade serous ovarian cancer (HGSC) at the single cell level, we performed single-cell RNA sequencing (scRNA-seq) on 48 tumor or ascites samples from 29 HGSC patients. This data set includes paired scRNA-seq data from chemo-naive and post-neoadjuvant chemotherapy (IDS) samples of 22 HGSC patients.

2024-10-08 | GSE266577 | GEO

Unraveling Tumor-Immune Heterogeneity in Advanced Ovarian Cancer Uncovers Immunogenic Effect of Chemotherapy [naïve]

Project description:In metastatic cancer, the degree of heterogeneity of the tumor-immune microenvironment and its molecular underpinnings remain largely unstudied. To characterize the tumor-immune interface at baseline and during neoadjuvant chemotherapy in high-grade serous ovarian cancer (HGSOC), we performed immunogenomics analysis of treatment-naive and paired pre/post-chemotherapy treated samples. In treatment-naive HGSOC, we find that immune cell-excluded and inflammatory microenvironments co-exist within the same individuals and within the same tumor sites, indicating ubiquitous variability in immune cell infiltration. Analysis of tumor microenvironment cell composition, DNA copy number, mutations and gene expression showed that immune cell exclusion was associated with amplification of Myc target genes and increased expression of canonical Wnt signaling in treatment-naive HGSOC. Following neoadjuvant chemotherapy, increased natural killer cell infiltration and oligoclonal expansion of T cells were detected. We demonstrate that the tumor-immune microenvironment of advanced HGSOC is intrinsically heterogeneous and that chemotherapy induces local immune activation, suggesting that chemotherapy can potentiate the immunogenicity of immune-excluded HGSOC tumors. The goal of this particular experiment was quantify RNA expression using microarray technology, and then evaluate differences in the trasncirptomic landscape of treatment naïve metastatic high grade serous ovarian cancer.

2020-03-14 | GSE146964 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data